Aethlon Medical Q1 FY2024 net loss $3.3M, cash $12.9M; Hemopurifier progress

AETHLON MEDICAL INC

2023-Q1 EPS reported -$0.14

Net loss widened to $3.3M for quarter ended June 30, 2023 from $2.9M a year ago; operating expenses rose 17.3% to $3.4M.
Cash balance $12.9M at quarter end; raised $1.1M net proceeds via at-the-market equity facility with H.C. Wainwright.
COVID-19 ICU trial in India remains open; second site Maulana Azad Medical College received Ethics Board approval.
Entered research collaboration with 34 Lives to test Hemopurifier in machine perfusion of recovered kidneys.
Oncology feasibility trial in Australia with NAMSA for solid tumors failing anti-PD-1 therapy is ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AETHLON MEDICAL INC reported first quarter ended June 30, 2023 results: net income approximately $3.3 million.

Period: first quarter ended June 30, 2023
Net income: approximately $3.3 million
Result: reported results

Exact text from the filing

As a result of the above factors, the company’s net loss increased to approximately $3.3 million in the three months ended June 30, 2023, from approximately $2.9 million in the three months ended June 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

AETHLON MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001683168-23-005510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.